Rockwell Medical Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
September 14 2022 - 4:15PM
Business Wire
Rockwell Medical, Inc. (Nasdaq: RMTI) (“Rockwell Medical” or the
“Company”), a commercial healthcare company focused on providing
life-sustaining products for patients suffering from blood
disorders and diseases associated with the kidney, today announced
that the Compensation Committee of the Company’s Board of Directors
approved the grant of stock options to purchase an aggregate of
66,000 shares of the Company’s common stock to three new employees
(the “Inducement Grants”) on September 9, 2022 (the “Grant Date”).
The Inducement Grants have been granted outside of the Company’s
2018 Long Term Incentive Plan (“Plan”) but remain subject to the
terms and conditions of such Plan. The Inducement Grants were
granted as an inducement material to these individuals entering
into employment with Rockwell Medical in accordance with Nasdaq
Listing Rule 5635(c)(4).
The Inducement Grants have an exercise price per share that is
equal to the closing price of the Company’s common stock on the
Grant Date. The Inducement Grants will vest in equal annual
installments on each of the first four anniversaries of the Grant
Date, subject to continued employment through the applicable
vesting dates.
About Rockwell Medical
Rockwell Medical is a commercial healthcare company focused on
providing life-sustaining products for patients suffering from
blood disorders and diseases associated with the kidney. Rockwell
is the second largest supplier of acid and bicarbonate concentrates
for dialysis patients in the United States. The Company is
developing and commercializing a next-generation, proprietary
parenteral iron technology platform, Ferric Pyrophosphate Citrate
(“FPC”), which has the potential to transform treatment options for
iron deficiency in multiple disease states, reduce healthcare costs
and improve patients' lives. Rockwell has two FDA-approved
therapies indicated for patients undergoing hemodialysis, which are
the first two products developed from the FPC platform. Rockwell is
also advancing its FPC platform by developing FPC for the treatment
of iron deficiency anemia in patients outside of dialysis, who are
receiving medications in the home infusion setting. For more
information, visit www.RockwellMed.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220914005818/en/
Heather R. Hunter (248) 432-1362 IR@RockwellMed.com
Rockwell Medical (NASDAQ:RMTI)
Historical Stock Chart
From Aug 2024 to Sep 2024
Rockwell Medical (NASDAQ:RMTI)
Historical Stock Chart
From Sep 2023 to Sep 2024